NCT03646058View on ClinicalTrials.gov

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

PHASE3RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

October 10, 2021

Primary Completion Date

October 31, 2026

Study Completion Date

January 31, 2027

Conditions
Suicidal IdeationMajor Depressive Episode
Interventions
DRUG

Buprenorphine

Buprenorphine, 0.4mg pills, sublingual

DRUG

Placebo

Placebo pills, sublingual, specifically made to mimick buprenorphine pills

Trial Locations (9)

30029

RECRUITING

CHU Nîmes, Nîmes

31059

NOT_YET_RECRUITING

Chu Toulouse Hopital Purpan, Toulouse

33076

NOT_YET_RECRUITING

Ch Perrens, Bordeaux

37540

RECRUITING

CHU de Tours, Tours

44000

RECRUITING

CAPPA Jacques PREVERT, Nantes

69003

RECRUITING

Hospices Civils de Lyon, Lyon

75674

RECRUITING

CH Sainte-Anne, Paris

86021

RECRUITING

CH Henri Laborit, Poitiers

94270

RECRUITING

CHU Bicêtre, Le Kremlin-Bicêtre

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nīmes

OTHER